Conolidine’s analgesic results stem from its interaction with non-opioid pain pathways. Unlike opioids, which bind to µ-opioid receptors during the central nervous technique, conolidine modulates alternate molecular targets. A Science Improvements analyze observed that conolidine interacts with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. B... https://guyi515wel9.wikipublicist.com/user